natgillin/translations-raw huggingface dataset:
Velmetia should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 mL/min) (see sections 4.3 and 4.4).
Zdravila Velmetia se ne sme uporabljati pri bolnikih z zmerno ali hudo ledvično okvaro (kreatininski očistek < 60 ml/min) (glejte poglavji 4.3 in 4.4).
Velosulin 100 IU/ml Solution for injection or infusion in a vial Insulin human (rDNA)
Velosulin 100 i.e./ml raztopina za injiciranje ali infundiranje v viali humani insulin (rDNA)
Velosulin 100 IU/ml solution for injection or infusion in a vial Insulin human( rDNA)
Velosulin 100 i.e./ml raztopina za injiciranje ali infundiranje v viali humani insulin (rDNA)
Velosulin 100 IU/ml solution for injection or infusion in a vial.
Velosulin 100 i.e./ml raztopina za injiciranje ali infundiranje v viali
Velosulin 100 IU/ml solution for injection or infusion Insulin human (rDNA)
Velosulin 100 i.e./ml raztopina za injiciranje ali infundiranje humani insulin (rDNA)
Velosulin contains metacresol, which may cause allergic reactions.
Velosulin vsebuje metakrezol, ki lahko povzroci alergijske reakcije.
Velosulin is a fast-acting insulin and may be used in combination with certain long-acting insulin products.
Velosulin je hitrodelujoc insulin in se lahko uporablja v kombinaciji z nekaterimi dolgodelujocimi insulinskimi zdravili.
Velosulin is a fast-acting insulin.
Velosulin je hitrodelujoci insulin.
Velosulin is human insulin to treat diabetes.
Velosulin je humani insulin za zdravljenje diabetesa.
Velosulin may cause hypoglycaemia (low blood sugar).
Velosulin lahko povzroci hipoglikemijo (nizek krvni sladkor).
Velosulin must be protected from excessive heat and sunlight.
Velosulin je treba zašcititi pred cezmerno toploto in soncno svetlobo.
Velosulin should never be mixed with any other insulin products when used in a pump.
Ce se Velosulin uporablja v crpalki, se ga nikoli ne sme mešati z nobenim drugim insulinom.
Velosulin should never be mixed with any other insulin when used in a pump.
Ce Velosulin uporabljate v crpalki, ga nikoli ne smete mešati z nobenim drugim insulinom.
Velosulin should not be disposed of via wastewater or household waste.
Zdravila Velosulin ne smete odvreci v odpadne vode ali med gospodinjske odpadke.
Velosulin should not be mixed with insulin zinc suspensions since the phosphate buffer may interact with the zinc in the suspension and alter the timing of action of the insulin in an unpredictable way.
Zdravila Velosulin se ne sme mešati s suspenzijami insulina s cinkom, ker lahko fosfatni pufer reagira s cinkom v suspenziji, kar nepredvidljivo spremeni casovni potek delovanja insulina.
Velpatasvir AUC increases in a nearly dose proportional manner over the dose range of 25 mg to
Vrednost AUC za velpatasvir je skoraj sorazmerna z odmerkom v razponu odmerka 25–150 mg.
Velpatasvir is > 99.5% bound to human plasma proteins and binding is independent of drug concentration over the range of 0.09 μg/mL to 1.8 μg/mL.
Velpatasvir se > 99,5-odstotno veže na humane beljakovine v plazmi, kar ni odvisno od koncentracije zdravila v razponu 0,09–1,8 μg/ml.
Velpatasvir is also a substrate of drug transporter OATP1B.
Velpatasvir je prav tako substrat prenašalca OATP1B.
Velpatasvir is an inhibitor of drug transporter P-gp, breast cancer resistance protein (BCRP), organic anion-transporting polypeptide (OATP) 1B1 and OATP1B3.
Velpatasvir je zaviralec prenašalca P-gp, proteina odpornosti pri raku dojke (BCRP, breast cancer resistance protein), transportnega polipeptida organskih anionov (OATP, organic anion-transporting polypeptide) 1B1 in OATP1B3.
Velphoro 500 mg chewable tablets
Velphoro 500 mg žvečljive tablete
Velphoro 500 mg chewable tablets iron as sucroferric oxyhydroxide
Velphoro 500 mg žvečljive tablete železo v obliki saharoznega železovega oksihidroksida
Velphoro contains sucrose and starches (carbohydrates)
Zdravilo Velphoro vsebuje saharozo in škrob (ogljikovi hidrati)
Velphoro contains sucrose.
Zdravilo Velphoro vsebuje saharozo.
Velphoro has been administered to over 245 seniors (≥65 years of age) according to the approved dosing regimen.
V skladu z odobrenim režimom odmerjanja so zdravilo Velphoro dajali več kot 245 starostnikom (≥ 65 let).
Velphoro has no or negligible influence on the ability to drive and use machines.
Zdravilo Velphoro nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Velphoro is a medicine that contains the active substance sucroferric oxyhydroxide, which is made up from iron, sugar (sucrose) and starches.
Velphoro je zdravilo, ki vsebuje zdravilno učinkovino saharoznega železovega oksihidroksida, ki je sestavljena iz železa, sladkorja (saharoza) in škroba.
Velphoro should only be taken by mouth.
Zdravilo Velphoro se jemlje samo peroralno (skozi usta).
Velphoro was as effective as sevelamer in reducing patients’ blood-phosphate levels and maintaining this effect.
Zdravilo Velphoro je bilo pri zniževanju ravni fosfatov v krvi bolnikov in ohranjanju tega učinka enako učinkovito kot sevelamer.
Vemurafenib (N=352)
vemurafenib (N = 352)
Vemurafenib inhibited CYP2C8 in vitro.
Vemurafenib je in vitro zaviral CYP2C8.
Vemurafenib is a moderate CYP1A2 inhibitor.
Vemurafenib je zmeren zaviralec CYP1A2.
Vemurafenib is a substrate and inhibitor of P-gp in vitro.
Vemurafenib je substrat in zaviralec P-gp in vitro.
Vemurafenib is an inhibitor of BRAF serine-threonine kinase.
Vemurafenib je zaviralec BRAF serin-treonin kinaze.
Vemurafenib may decrease the plasma exposure of substances predominantly metabolised by CYP3A4.
Vemurafenib lahko zmanjša plazemsko izpostavljenost zdravilom, ki se presnavljajo pretežno s CYP3A4.
Vemurafenib may increase the plasma exposure of medicinal products predominantly metabolised by CYP1A2 and decrease the plasma exposure of medicines predominantly metabolised by CYP3A4, including oral contraceptives.
Vemurafenib lahko poveča izpostavljenost plazmi tistih zdravil, ki se pretežno presnavljajo s CYP1A2 in zmanjša izpostavljenost plazmi zdravil, ki se pretežno presnavljajo s CYP3A4, vključno s peroralnimi kontraceptivi.
Vemurafenib may thus increase the plasma exposure of substances predominantly metabolised by CYP1A2 (e.g. agomelatine, alosetron, duloxetine, melatonin, ramelteon, tacrine, tizanidine, theophylline) and dose adjustments may be considered, if clinically indicated.
Vemurafenib tako lahko poveča izpostavljenost v plazmi tistim snovem, ki se presnavljajo pretežno s CYP1A2 (npr. agomelatinu, alosetronu, duloksetinu, melatoninu, ramelteonu, takrinu, tizanidinu, teofilinu); v takem primeru se lahko razmisli o prilagoditvi odmerka, če je klinično indicirano.
Vemurafenib pharmacokinetics could be affected by medicines that inhibit or influence P-gp (e.g. verapamil, clarithromycin, cyclosporine, ritonavir, quinidine, dronedarone, amiodarone, itraconazole, ranolazine) (see section 4.5).
Na farmakokinetiko vemurafeniba bi lahko vplivala zdravila, ki zavirajo ali vplivajo na P-gp (npr. verapamil, klaritromicin, ciklosporin, ritonavir, kinidin, dronedaron, amiodaron, itrakonazol, ranolazin) (glejte poglavje 4.5).
Vemurafenib should be used with caution in combination with potent inhibitors of CYP3A4, glucuronidation and/or transport proteins (e.g. ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, nefazodone, atazanavir).
Vemurafenib je treba uporabljati previdno v kombinaciji z močnimi inhibitorji CYP3A4, glukuronidacije in/ali prenašalnih beljakovin (npr. ritonavirjem, sakvinavirjem, telitromicinom, ketokonazolom, itrakonazolom, vorikonazolom, posakonazolom, nefazodonom, atazanavirjem).
Vendel Park, Tormasrét u.
Medicus Partner GmbH Vendel Park, Tormasrét u.
venipuncture set alcohol swabs for single use 2 dry swabs
pribor za vensko punkcijo alkoholna tampona za enkratno uporabo 2 suha tampona
Venipuncture site haemorrhage
krvavitev na mestu venepunkcije
venlafaxine, trazodone - used for depression
venlafaksin, trazodon - za depresijo
Veno occlusive liver disease
veno-okluzivna bolezen jeter
Veno occlusive liver disease
veno-okluzivna jetrna bolezen
Veno occlusive liver disease *
veno-okluzivna jetrna bolezen
Veno-occlusive diseased
driskaa bruhanjea zaprtosta navzeaa
Veno-occlusive diseased
hipotenzija
Veno-occlusive diseased
venookluzivna bolezend
Veno-occlusive diseased
vensko- okluzivna bolezend
Veno-occlusive diseased
vensko-okluzivna bolezend
Venoocclusive liver disease
venookluzivna bolezen jeter
Venoocclusive liver disease Hepatomegaly Jaundice
venookluzivna bolezen jeter hepatomegalija zlatenica
Venous and arterial thromboses3, Hypertension
venske in arterijske tromboze3, hipertenzija
Venous blood clots are likely to occur in approximately 8 out of 100 patients.
Strdki venske krvi se lahko pojavijo pri približno 8 od 100 bolnikov.
Venous disorder
bolezen ven
Venous disorder
Venska bolezen (S3/4: 0,6 %)
Venous disorder (G3/4: 0.6%)
bolezen ven (S3/4: 0,6 %)
Venous disorder (G3/4: 0.6%)
venska bolezen (S 3/4: 0,6 %)
Venous disorder (G3/4: 0.6%)
venska bolezen (S3/4: 0,6 %)
Venous disorder (G3/4: 0.6%)
venska bolezen (S3/4: 0,6%)
Venous disorder (G3/4: 0.6%)
venske motnje (S3/4: 0,6 %)
Venous embolic and thrombotic events (see section 4.4)
Venski embolični in trombotični dogodki (glejte poglavje 4.4)
Venous embolic and thrombotic eventsc,d,i
venski embolični in trombotični dogodki c, d, i
Venous embolic or thrombotic events (VTE) occurred in 3.3% of patients who received Pom + LD-Dex, and 2.0% of patients who received HD-Dex.
Venske embolične ali trombotične dogodke (VTE) je imelo 3,3 % bolnikov, ki so prejemali Pom + NO- deks, in 2,0 % bolnikov, ki so prejemali VO-deks.
Venous occlusive reactions (treatment-emergent frequencies) occurred in 5.0% of patients.
Venske okluzivne reakcije (pogostnosti v povezavi z zdravljenjem) so se pojavile pri 5 % bolnikov.
Venous thromboembolic event g
venska trombembolijag
Venous thromboembolic eventd
venski trombembolični dogodkid
Venous Thromboembolic Events
Venski trombembolični dogodki
Venous thromboembolic events (including, pulmonary embolism, retinal vein thrombosis, deep vein thrombosis and thrombophlebitis)
venski trombembolični dogodki (vključno s pljučno embolijo, trombozo mrežnične vene, globoko vensko trombozo in tromboflebitisom)
Venous thromboembolic events (VTE)
Venski trombembolični dogodki
Venous thromboembolic events (VTE) and arterial thromboembolic events (ATE), including fatal cases, were observed with necitumumab in combination with gemcitabine and cisplatin (see also section 4.8).
Venske trombembolične dogodke in arterijske trombembolične dogodke, vključno s smrtnimi primeri, so opazili pri zdravljenju z necitumumabom v kombinaciji z gemcitabinom in cisplatinom (glejte tudi poglavje 4.8).
Venous thromboembolic events (VTE) include deep venous thrombosis and pulmonary embolism.
Venski trombembolični dogodki (VTE), vključujejo globoko vensko trombozo in pljučno embolijo.
Venous thromboembolic events have rarely been reported.
Opisani so bili redki primeri venskih trombembolij.
Venous thromboembolic events have rarely been reported.
Opisani so bili redki primeri venskih tromboembolij.
Venous thromboembolic events have rarely been reported.
Redko so poročali o venskih trombembolijah.
Venous thromboembolic events were reported for 1 (1.2%) subject in the sunitinib arm and 5 (6.1%) subjects in the placebo arm in the phase 3 pNET study.
V študiji 3. faze pri pNET so o venskih trombemboličnih dogodkih poročali pri enem bolniku (1,2 %), ki je prejemal sunitinib, in pri 5 bolnikih (6,1 %), ki so prejemali placebo.
Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^
venski trombembolični dogodki, pretežno globoka venska tromboza in pljučna embolija^ pogosti
Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^ Common
venski trombembolični dogodki, pretežno globoka venska tromboza in pljučna embolija^ pogosti
venous thromboembolism
venska tromboembolija
Venous thromboembolism (1)
venska trombembolija (1)
Venous thromboembolism (including deep vein thrombosis, venous thrombosis)
venska trombembolija (vključno z globoko vensko trombozo, vensko trombozo)
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
venska trombembolija (vključno s pljučno embolijo in globoko vensko trombozo)
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
venska trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) hipertenzija sinkopa
Venous thromboembolism (VTE)
venska tombembolija (VTE)
Venous thromboembolism - current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
Venska trombembolija - obstoječa VTE (zdravljena z antikoagulanti) ali VTE v anamnezi (npr. globoka venska tromboza [DVT - deep venous thrombosis] ali pljučna embolija [PE – pulmonary embolism]).
Venous thromboembolism - current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
Venska trombembolija - obstoječa VTE (zdravljena z antikoagulanti) ali VTE v anamnezi (npr. globoka venska tromboza [DVT – deep venous thrombosis] ali pljučna embolija [PE – pulmonary embolism]).
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma and with monotherapy in myelodysplastic syndromes.
Vensko trombembolijo so opazili v manjši meri pri lenalidomidu v kombinaciji z melfalanom in prednizonom pri novo diagnosticiranem diseminiranem plazmocitomu in pri monoterapiji pri mielodisplastičnih sindromih.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma.
Vensko trombembolijo so opazili v manjši meri pri lenalidomidu v kombinaciji z melfalanom in prednizonom pri novo diagnosticiranem diseminiranem plazmocitomu.
Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]);
Venska trombembolija – obstoječa VTE (zdravljena z antikoagulanti) ali v anamnezi (npr. globoka venska tromboza [DVT, deep venous thrombosis] ali pljučna embolija [PE]).
Venous thromboembolism, Hypertension
venska trombembolija, hipertenzija
venous thromboembolism, including thrombophlebitis, venous thrombosis and pulmonary embolism
venski trombembolizem, vključno s tromboflebitisom, vensko trombozo in pljučno embolijo
Venous thromboembolisma, hot flushes
venska trombembolijaa, navali vročine
venous thrombosis deep limb, shock, infarction
globoka venska tromboza v udih, šok, infarkt
Venous thrombosis limb
venska tromboza okončine
venous thrombosis, arterial thrombosis, thrombophlebitis, arterial stenosis, intermittent claudication, flushing
venska tromboza, arterijska tromboza, tromboflebitis, arterijska stenoza, intermitentna klavdikacija, vročinski oblivi
venous thrombosis, flushing
venska tromboza, rdečica
Venous thrombosis, phlebitis, venous burning, hot flush
venska tromboza, flebitis, občutek pečenja v veni, vročinski oblivi
Venous thrombosis/thromboembolism
Hipertenzija Venska tromboza/trombembolija
Venous thrombosis/thromboembolism
venska tromboza/ tromboembolija
Venta-Neb nebuliser (2 ml ampoule with white and pink rings)
Nebulator Venta-Neb (2-mililitrska ampula z belim in rožnatim obročem)
Venta-Neb prompts the patient to inhale by an optical and an acoustic signal.
Nebulator Venta-Neb z optičnim in zvočnim signalom spodbudi bolnika, da vdihne.
Ventavis 10 microgram/ml nebuliser solution
Ventavis 10 mikrogramov/ml inhalacijska raztopina za nebulator
Ventavis 10 microgram/ml nebuliser solution (1 ml ampoule)
Ventavis 10 mikrogramov/ml inhalacijska raztopina za nebulator (1 ml ampula)
Ventavis 10 microgram/ml nebuliser solution 2 years.
Ventavis 10 mikrogramov/ml inhalacijska raztopina za nebulator 2 leti
Ventavis 10 microgram/ml nebuliser solution Clear, colourless solution.
Ventavis 10 mikrogramov/ml inhalacijska raztopina za nebulator bistra, brezbarvna raztopina
Ventavis 10 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib, the Venta-Neb or the I-Neb AAD system).
Zdravilo Ventavis 10 mikrogramov/ml raztopina za nebulator se inhalira z nebulatorjem, ki vam ga je predpisal zdravnik (Breelib, Venta-Neb ali I-Neb AAD).
Ventavis 10 microgram/ml, nebuliser solution Iloprost
Ventavis 10 mikrogramov/ml inhalacijska raztopina za nebulator iloprost
Ventavis 10 microgram/ml, nebuliser solution Iloprost
Ventavis 10 mikrogramov/ml, inhalacijska raztopina za nebulator iloprost
Ventavis 10 microgram/ml:
Ventavis 10 mikrogramov/ml
Ventavis 20 microgram/ml nebuliser solution
Ventavis 20 mikrogramov/ml inhalacijska raztopina za nebulator
Ventavis 20 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib or the I-Neb AAD nebuliser).
Zdravilo Ventavis 10 mikrogramov/ml raztopina za nebulator se inhalira z nebulatorjem, ki vam ga je predpisal zdravnik (Breelib, Venta-Neb ali I-Neb AAD).
Ventavis 20 microgram/ml, break the glass ampoule and pour the complete contents of 1 ml into the nebuliser medication golden chamber.
20 mikrogramov/ml, prelomite stekleno ampulo in celotno vsebino 1 mililitra zlijte v zlat prostor za zdravilo v nebulatorju.
Ventavis 20 microgram/ml:
Ventavis 20 mikrogramov/ml
Ventavis contains small amounts of ethanol (alcohol), less than 100 mg per dose.
Zdravilo Ventavis vsebuje majhne količine etanola (alkohola), in sicer manj kot 100 mg na odmerek.
Ventavis has major influence on the ability to drive and use machines for patients experiencing hypotensive symptoms such as dizziness.
Zdravilo Ventavis ima pomemben vpliv na sposobnost vožnje in upravljanja strojev pri bolnikih s simptomi hipotenzije, kot je omotica.
Ventavis inhalation might entail the risk of inducing bronchospasm, especially in patients with bronchial hyperactivity (see section 4.8).
Zdravilo Ventavis lahko povzroči tveganje za pojav bronhospazma, predvsem pri bolnikih z bronhialno hiperaktivnostjo (glejte poglavje 4.8).
Ventavis is a clear, colourless nebuliser solution for inhalation with the Breelib, the I-Neb or the Venta-Neb nebuliser.
Zdravilo Ventavis je bistra, brezbarvna inhalacijska raztopina za inhaliranje z nebulatorjem Breelib, I- Neb ali Venta-Neb.
Ventavis is an inhaled formulation of iloprost, a substance that is very similar to prostacyclin, a naturally occurring molecule that causes blood vessels to dilate (expand).
Zdravilo Ventavis je inhalacijska formulacija iloprosta, tj. učinkovine, ki je zelo podobna prostaciklinu – naravno prisotni molekuli, ki povzroča dilatacijo (širjenje) krvnih žil.
Ventavis lowers blood pressure and may cause dizziness or light-headedness in some people.
Zdravilo Ventavis znižuje krvni tlak in lahko pri nekaterih ljudeh povzroči omotico ali občutek omedlevice.
Ventavis should only be initiated and monitored by a physician experienced in the treatment of pulmonary hypertension.
Zdravljenje z zdravilom Ventavis lahko uvede in spremlja le zdravnik, ki ima izkušnje z zdravljenjem pljučne hipertenzije.
Ventavis therapy should only be initiated by a physician experienced in treatment of pulmonary hypertension.
Zdravljenje z zdravilom Ventavis lahko uvede le zdravnik z izkušnjami z zdravljenjem pljučne hipertenzije.
Ventavis was originally authorised under ‘exceptional circumstances’ because, as the disease is rare, limited information was available at the time of approval.
Zdravilo Ventavis je bilo prvotno odobreno v „izjemnih okoliščinah“, saj so bile zaradi redkosti bolezni ob odobritvi dovoljenja na voljo le omejene informacije.
Ventilation support
Ventilacijska podpora
Ventilator-associated pneumonia
Pljučnica zaradi uporabe respiratorja
ventricular
Ni znano
Ventricular
Prekatna
Ventricular arrhythmia
Ventrikularna aritmija
Ventricular arrhythmia
ventrikularne aritmije
Ventricular arrhythmia*,
epistaksa, zamašenost sinusov
Ventricular arrhythmias (including ventricular tachycardia, torsade de pointes) have been reported in patients treated with telithromycin and sometimes occurred within a few hours of the first dose (see section 4.8).
Pri bolnikih, ki so se zdravili s telitromicinom, so poročali o ventrikularni aritmiji (vključno z ventrikularno tahikardijo, torsade de pointes), katera se je včasih pojavila že v nekaj urah po zaužitju prvega odmerka (glejte poglavje 4.8).
Ventricular extrasystoles
ventrikularne ekstrasistole
Ventricular extrasystoles
ventrikularne ekstrasistolije
Ventricular Extrasystoles Bradycardia
ventrikularna ekstrasistola bradikardija
Ventricular fibrillation (rare), QT prolongation (rare), Torsade de pointes (rare), Bradycardia (rare), Vasospasm (rare)
ventrikularna fibrilacija (redki), podaljšanje intervala QT (redki), torsade de pointes (redki), bradikardija (redki), vazospazem (redki)
ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, supraventricular tachycardia
ventrikularna fibrilacija, ventrikularne ekstrasistole, ventrikularna tahikardija, podaljšanje intervala QT, supraventrikularna tahikardija
Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed in tacrolimus treated patients on rare occasions.
Ventrikularno hipertrofijo ali hipertrofijo septuma, opisani kot kardiomiopatije, so opazili v redkih primerih zdravljenja bolnikov s takrolimusom.
Ventricular repolarisation abnormalities may have been contributory factors.
Poleg tega bi bila lahko vpletena tudi nenormalna repolarizacija srčnih prekatov.
ventricular septal defect
in ventrikularni septalni defekt
Ventricular tachycardia
prekatna tahikardija
Ventricular tachycardia Congestive heart failure
ventrikularna tahikardija kongestivna srčna odpoved
Ventricular tachycardia, Ventricular arrhythmia and torsade de pointes
ventrikularna tahikardija, ventrikularna aritmija in torsade de pointes
Ventricular tachycardia/f ibrillation, sudden death (see section 4.4)11
Prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fib rillation, sudden death (see section 4.4)11
Prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibri llation, sudden death (see section 4.4)11
Prekatna tahikardija/fibrila cija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrill ation, sudden death (see section 4.4) 11
Prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrill ation, sudden death (see section 4.4)11
prekatna tahikardija/fibr ilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrilla tion, sudden death (see section 4.4)11
prekatna tahikardija/fi brilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillat ion sudden death (see section 4.4)11
Prekatna tahikardija/fibril acija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillat ion, sudden death (see section 4.4)11
Prekatna tahikardija/fibrila cija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillati on, sudden death (see section 4.4)11
prekatna tahikardija/ fibrilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillati on, sudden death (see section 4.4)11
prekatna tahikardija/fi brilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillati on, sudden death (see section 4.4)11
prekatna tahikardija/fibr ilacija, nenadna smrt (glejte poglavje 4.4) 11
Ventricular tachycardia/fibrillatio n, sudden death (see section 4.4)11
prekatna tahikardija/fi brilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillatio n, sudden death (see section 4.4)11
prekatna tahikardija/fibr ilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillatio n, sudden death (see section 4.4)11
prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillation
Prekatna tahikardija/fibrilaci
Ventricular tachycardia/fibrillation, sudden death (see section 4.4)11
Prekatna tahikardija/fibr ilacija, nenadna smrt (glejte poglavje 4.4)11
Ventricular tachycardia/fibrillation, sudden death (see section 4.4)11
prekatna tahikardija/fibrilacij a, nenadna smrt (glejte poglavje 4.4)11